

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 26 avril 2023 10:33

Laboratory Information

Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	LEPTOSPIROSIS
Address of laboratory:	39 Kessels Road, Coopers Plains, (P.O. Box 594, Archerfield), Queensland, AUSTRALIA 4108
Tel.:	+61 7 3096 2818
E-mail address:	megan.staples@health.qld.gov.au
Website:	www.health.qld.gov.au/fss
Name (including Title) of Head of Laboratory (Responsible Official):	Megan Staples
Name (including Title and Position) of WOA Reference Expert:	TO BE DECIDED - Megan Staples PROPOSED
Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
Microscopic Agglutination Test	Yes	23030	19984
Direct diagnostic tests		Nationally	Internationally

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
Culture Media	Microscopic Agglutination Test	Yes	<500ml	0	1	Asia and Pacific

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Members?

Yes

NAME OF WOA MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
HONG KONG	2022-03-23	MAT	429	429
HONG KONG	2022-07-25	MAT	322	322
HONG KONG	2022-11-11	MAT	110	110

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

NAME OF THE WOA MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
AUSTRALIA	Advice around MAT diagnostics	Via email and phone

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Leptospira in domestic canines and felines in Hong Kong	~2 years	Surveillance of Leptospira serovar prevalence in domestic canines and felines in Hong Kong	City University of Hong Kong	HONG KONG

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:
Incidence data of Leptospirosis in Australia

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

Usually 1-2

Nil this year though the laboratory has often been called upon for contributions/authorship to manuscripts in years past and future articles are planned.

b) International conferences:

Usually 1 every 2 years

International Leptospirosis Society Scientific Meeting, attended by Megan Staples in Nov 2021 (Bangkok). Presented initial work on Whole Genome Sequencing of Leptospira spp. of the laboratory reference culture collection

c) National conferences:

1-2

Nil presented at this year, though Megan Staples attended the Communicable Diseases and Immunisation Conference June 2022 as a virtual participant.

d) Other (Provide website address or link to appropriate information):

1

Leptospirosis Reference Laboratory website, which includes general Leptospirosis and related testing information and factsheets for Serovars of importance in the Australasian region. <https://www.health.qld.gov.au/public-health/forensic-and-scientific-services/testing-analysis/disease-investigation-and-analysis/leptospirosis-reference-laboratory/what-is-leptospirosis>

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

Yes

a) Technical visit :

b) Seminars : 1

c) Hands-on training courses:

d) Internships (> 1 month)

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
B	Australia	60

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO/IEC 17025	17025- Biological Accreditation Certification.PDF	17025- Bio.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Microscopic Agglutination Test	NATA
Culture	NATA
PCR	NATA

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

Risk Management Plan in place, with regular routine Risk Assessment review

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
International Leptospirosis Society Scientific Meeting	2022-11-13	Bangkok, Thailand	Presenting Poster	AN AUSTRALASIAN LEPTOSPIRA SPECIES GENOMIC DATABASE FOR THE IDENTIFICATION OF UNKNOWN ISOLATES AND DETERMINATION OF INFECTING SEROVARS DIRECTLY FROM SERUM IN A CULTURE INDEPENDENT MANNER

TOR10: NETWORK WITH WOA REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOA Member Countries
External Quality Assurance	Participant	20	Asia and Pacific

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOH?

No

29. Additional comments regarding your report:

Yes

Work has been restrained again due to Covid restrictions. Additionally, the previous longstanding Supervising Scientist stepped down from his role this past year, bringing in a leadership transition. With funding now secured for genomics research and further plans to develop capabilities and establish new networks we expect to report additional activities in 2023.